United States Patent 8,846,074: Scope, Claim Architecture, and Patent Landscape
US Drug Patent 8,846,074 claims a sublingual unit-dose film for apomorphine hydrochloride with a pyridoxine (vitamin B6) layer defined by specific quantitative ranges, plus optional excipient system controls and a pharmacokinetic performance statement. The patent also covers a Parkinson’s disease treatment method using the claimed composition.
What does the independent claim cover? (Claim 1 scope)
Claim 1 is the core composition claim. It requires all of the following:
- Dosage form: a unit dosage form for sublingual administration
- Form factor: a film with two layers
- Layer 1 composition: 2 to 60 mg of apomorphine hydrochloride
- Layer 2 composition: 25 ± 5% to 65 ± 5% (w/w) pyridoxine
In practical terms, Claim 1 is not a general “sublingual apomorphine” concept. It is a specific film architecture (two layers) with a specific pyridoxine loading band and a specific apomorphine dose range.
How do dependent claims expand or narrow scope? (Claims 2–16)
Claims 2–11 add excipient-system constraints that can narrow infringement to compositions matching those optional selections.
Plasticizing agent selection and loading
- Claim 2: film further comprises 3 to 12% (w/w) plasticizing agent
- Claim 3: plasticizer is a polyol, oleic acid, or triacetin
- Claim 4: plasticizer is a polyol selected from:
- sorbitol
- mannitol
- maltitol
- xylitol
- glycerol
- propylene glycol
- polyethylene glycol
These claims create multiple “fall-back” versions. If a competitor uses a polyol plasticizer within the allowed chemical set and within the 3 to 12% band, the claim coverage aligns.
Hydrolyzed starch excipient system
- Claim 5: film further comprises 1 to 50% (w/w) hydrolyzed starch
- Claim 6: hydrolyzed starch is dextrin or maltodextrin
This is a broad hydrolyzed starch window (1 to 50%), but it is anchored to the film and to the starch type.
Antioxidant and sulfite level
- Claim 7: film further comprises an antioxidant
- Claim 8: antioxidant system includes 0.05 to 2.5% (w/w) metabisulfite
If a competitor avoids metabisulfite, it may still fall within Claim 1 but may avoid the dependent claim set.
Permeation enhancer and specific agent
- Claim 9: film further comprises 0.2 to 5% (w/w) of a permeation enhancer
- Claim 10: permeation enhancer is glycerol monostearate
This adds a targeted mechanistic excipient route. If a competitor uses another enhancer or uses none, it may avoid Claims 9–10 while still potentially meeting Claim 1.
Cellulose-type polymers
- Claim 11: film comprises carboxymethylcellulose or hydroxypropyl cellulose or hydroxypropyl methyl cellulose or hydroxyethyl cellulose or methyl cellulose
This claim constrains polymer selection. It does not exclude other materials, but it requires at least one of the listed cellulose excipient classes.
Pyridoxine layer specificity and pH behavior
- Claim 18: alternatively specifies that layer 2 comprises 65 ± 5% (w/w) pyridoxine as the layer 2 makeup
Note the interplay: Claim 1 already requires layer 2 be within 25 ± 5% to 65 ± 5%. Claim 18 locks in a specific high-end band within that range.
- Claim 19: pyridoxine amount is such that placing the unit dosage form in 1 mL of unbuffered water at pH 7 produces a pH between 2.5 and 8.0
Claim 19 introduces a functional dissolution/pH outcome test, tying formulation composition to an in-use pH window after exposure in water.
What performance and dosing coverage exists? (Claims 12–16)
Pharmacokinetic statement
- Claim 12: following sublingual administration, unit dosage produces average circulating concentration of at least 3 ng/mL within 5 to 15 minutes
This is a performance criterion that can be used both for inclusion and for enforcement against formulations that do not reach the claimed early systemic exposure.
Multiple fixed apomorphine dose exemplars (nested dependent claims)
Claims 13–16 enumerate unit-dose apomorphine hydrochloride quantities:
- Claim 13: 12 ± 3 mg
- Claim 14: 22 ± 4 mg
- Claim 15: 30 ± 5 mg
- Claim 16: 35 ± 5 mg
These create multiple specific numeric “hooks.” If a competitor uses a different apomorphine amount outside these bands, it may avoid those dependent claims while still meeting Claim 1.
What method coverage exists? (Claim 17)
- Claim 17: method of treating Parkinson’s disease by sublingual administration of a composition of Claim 1, in an amount effective to treat the subject.
This ties therapeutic use directly to the composition of Claim 1.
Claim Coverage Map: What must be true for infringement?
Core infringement prerequisites (Claim 1)
A product likely needs to satisfy all of the following simultaneously:
| Element |
Requirement in Claim 1 |
Enforcement implication |
| Administration route |
Sublingual |
Must be designed/used for sublingual delivery |
| Dosage form |
Unit dosage form as a film |
Not tablets, sprays, strips without a film structure |
| Layer architecture |
First layer + second layer |
Single-layer films likely fall outside |
| Apomorphine amount (layer 1) |
2 to 60 mg apomorphine HCl |
Dose band is a gating feature |
| Pyridoxine amount (layer 2) |
25 ± 5% to 65 ± 5% (w/w) |
Formulation loading must match |
Dependent claim add-ons (Claims 2–11, 18–19)
Coverage expands if the product also matches optional features:
| Dependent feature |
Claims |
Product design signals |
| Plasticizer |
Claims 2–4 |
Must use 3–12% w/w plasticizer; chemical class in listed set |
| Hydrolyzed starch |
Claims 5–6 |
Must use 1–50% w/w dextrin/maltodextrin |
| Antioxidant + metabisulfite |
Claims 7–8 |
Must include 0.05–2.5% w/w metabisulfite (if asserting those dependent claims) |
| Permeation enhancer |
Claims 9–10 |
Must use 0.2–5% w/w glycerol monostearate |
| Cellulose polymer |
Claim 11 |
Film includes one of listed cellulose excipients |
| Pyridoxine in high band |
Claim 18 |
Layer 2 specifically at 65 ± 5% pyridoxine |
| Functional pH outcome |
Claim 19 |
Unit dose in 1 mL unbuffered water at pH 7 yields pH 2.5–8.0 |
Dependent claim add-ons tied to outcomes and fixed doses (Claims 12–16)
- Performance: Claim 12 creates a measurable bioavailability requirement (>=3 ng/mL within 5–15 min).
- Fixed dose exemplars: Claims 13–16 create numeric “landing zones” for apomorphine HCl loading.
Potential design-around levers (based on claim structure)
This is not legal advice. It is a technical claim-reading-based list of formulation attributes that can move a product out of specific dependent coverage while still risking Claim 1.
High-leverage design parameters
- Layer count and architecture
Claim 1 is expressly two-layer. A single-layer film or different layer organization can avoid the claim element.
- Pyridoxine loading band
Layer 2 pyridoxine must be within 25 ± 5% to 65 ± 5% (w/w) to meet Claim 1. Landing outside the band can avoid all dependent claims that depend on Claim 1.
- Apomorphine dose per unit (layer 1)
Claim 1 requires 2 to 60 mg per unit. Different unit doses can avoid Claim 1 and any dependent dose-specific claims.
- Functional pH outcome (Claim 19)
Even if pyridoxine is present, pH behavior after water exposure is a constraint.
- Specific excipient substitutions (dependent claims)
Claims 4, 6, 8, 10, and 11 narrow coverage if competitors change plasticizer chemistry, starch type, metabisulfite presence, permeation enhancer identity, or cellulose class selection.
Patent landscape: how this claim set typically positions against adjacent IP
The claims show an emphasis on three pillars that are commonly contested in apomorphine sublingual development:
- Route and dosage form: sublingual film unit dose with layered structure
- Combination with pyridoxine: pyridoxine as a co-ingredient with defined loading and pH behavior
- Early systemic exposure: rapid attainment of circulating apomorphine levels
Where this patent is strongest
- Products that are two-layer sublingual apomorphine films with pyridoxine as the major component of the second layer (25 ± 5% to 65 ± 5% w/w).
- Products that match 12/22/30/35 mg apomorphine HCl per unit.
- Products with measured early exposure: at least 3 ng/mL within 5–15 minutes.
Where this patent is weakest
- Single-layer films, gels, wafers without a two-layer structure.
- Sublingual products with pyridoxine outside the defined band, or with pyridoxine replaced with non-pyridoxine pH modifiers (even if they still achieve similar systemic profiles).
- Products that avoid metabisulfite, glycerol monostearate, or the listed cellulose excipients, as long as the product still does not meet Claim 1.
Key takeaways
- Claim 1 defines the invention: a two-layer sublingual film with 2–60 mg apomorphine HCl in layer 1 and 25 ± 5% to 65 ± 5% pyridoxine (w/w) in layer 2.
- Dependent claims add measurable and excipient-level constraints: plasticizer (3–12% and specified chemistry), hydrolyzed starch (1–50% dextrin/maltodextrin), antioxidant with metabisulfite (0.05–2.5%), permeation enhancer (0.2–5% glycerol monostearate), and specific cellulose excipients.
- Enforcement hooks include performance and dosing bands: >=3 ng/mL within 5–15 min and specific apomorphine per-unit amounts (12 ± 3 mg; 22 ± 4 mg; 30 ± 5 mg; 35 ± 5 mg).
- Method claim 17 is straightforward: treating Parkinson’s disease using the composition of Claim 1 by sublingual administration.
- Design-around levers are clear from the claim language: disrupt layer architecture, move pyridoxine loading outside the stated range, adjust apomorphine unit dose, or change excipient identities tied to dependent claims.
FAQs
-
Does Claim 1 require pyridoxine to be the main second-layer component?
Yes. Claim 1 requires the second layer comprises 25 ± 5% to 65 ± 5% (w/w) pyridoxine.
-
Is the apomorphine dose range flexible?
Claim 1 allows 2 to 60 mg apomorphine HCl per unit in the first layer, while dependent claims specify 12 ± 3 mg, 22 ± 4 mg, 30 ± 5 mg, and 35 ± 5 mg.
-
What is the role of the two-layer film requirement?
Claim 1 expressly requires first and second layers. Single-layer sublingual formats are outside the literal two-layer element.
-
Is there an in-vivo performance requirement?
Yes. Claim 12 requires average circulating concentration of at least 3 ng/mL within 5 to 15 minutes after sublingual administration.
-
Can a formulation avoid dependent claims but still fall under Claim 1?
Yes. Dependent claims (plasticizer, starch, metabisulfite, permeation enhancer, cellulose excipient, pH outcome, fixed dose exemplars) can be avoided while still potentially meeting Claim 1 if the core film architecture and pyridoxine/apomorphine ranges are met.
References
- United States Patent 8,846,074 (claims as provided by user).
